Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Birtle A"'
Autor:
James, N.D., Pirrie, S.J., Pope, A.M., Barton, D., Andronis, L., Goranitis, I., Collins, S, Daunton, A., McLaren, D., O’Sullivan, J., Parker, C., Porfiri, E., Staffurth, J., Stanley, A., Wylie, J., Beesley, S., Birtle, A., Brown, J., Chakraborti, P., Hussain, S., Russell, M., Billingham, L.J.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::386fa16c19ee21eb3f4ff85fa763d5e3
https://eprints.whiterose.ac.uk/101667/10/Manuscript_BJUI_final_accepted.pdf
https://eprints.whiterose.ac.uk/101667/10/Manuscript_BJUI_final_accepted.pdf
Autor:
Matthew R. Sydes, David Matheson, David P. Dearnaley, Tony Elliott, Gerhardt Attard, Noel W. Clarke, Melissa R. Spears, J. Martin Russell, Chris Parker, Jim Barber, Alison Birtle, Johann S. de Bono, Narayanan Srihari, Francesca Schiavone, Joe M. O'Sullivan, Malcolm David Mason, Isabel Syndikus, Jan Wallace, Mahesh K. B. Parmar, Nicholas D. James, A.W.S. Ritchie, Daniel S. Engeler, Delia Pudney
MPORTANCE:\ud \ud The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e18432d25afd0d6774397b9ddf36c64
https://orca.cardiff.ac.uk/id/eprint/89456/1/coi150083.pdf
https://orca.cardiff.ac.uk/id/eprint/89456/1/coi150083.pdf
Autor:
James, Nicholas D., Spears, Melissa R., Clarke, NoelW., Dearnaley, David P., Mason, Malcolm D., Parker, Christopher C., Ritchie, AlastairW. S., Martin Russell, J., Schiavone, Francesca, Attard, Gerhardt, De Bono, Johann S., Birtle, Alison, Engeler, Daniel S., Elliott, Tony, Matheson, David, O'Sullivan, Joe, Pudney, Delia, Srihari, Narayanan, Wallace, Jan, Barber, Jim
Publikováno v:
JAMA Oncology; Mar2016, Vol. 2 Issue 3, p348-357, 10p
Autor:
James ND; University Hospital Birmingham NHS Foundation Trust, Birmingham, England., Pirrie SJ; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, England., Pope AM; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, England., Barton D; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, England., Andronis L; Health Economics Unit, University of Birmingham, England., Goranitis I; Health Economics Unit, University of Birmingham, England., Collins S; Cancer Research UK Clinical Trials Unit, Birmingham, England., Daunton A; University Hospital Birmingham NHS Foundation Trust, Birmingham, England., McLaren D; Department of Clinical Oncology, Western General Hospital, Edinburgh, Scotland., O'Sullivan J; Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland., Parker C; The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, Sutton, England., Porfiri E; University Hospital Birmingham NHS Foundation Trust, Birmingham, England., Staffurth J; Institute of Cancer and Genetics, Cardiff University, Cardiff, Wales., Stanley A; Department of Oncology Pharmacy, Birmingham City Hospital, Birmingham, England., Wylie J; Department of Clinical Oncology, The Christie Hospital, Manchester, England., Beesley S; Department of Clinical Oncology, Kent Oncology Centre, Maidstone, England., Birtle A; Rosemere Cancer Centre, Royal Preston Hospital, Lancashire, England., Brown J; Cancer Research UK Clinical Centre at Leeds, University of Leeds, St James' University Hospital, Leeds, England., Chakraborti P; Department of Oncology, Royal Derby Hospital, Derby, England., Hussain S; Institute of Translational Medicine, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, England., Russell M; Beatson West of Scotland Cancer Centre, Glasgow, Scotland., Billingham LJ; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, England.
Publikováno v:
JAMA oncology [JAMA Oncol] 2016 Apr; Vol. 2 (4), pp. 493-9.